Advertisement

Clinical Drug Investigation

, Volume 26, Issue 4, pp 175–183 | Cite as

Closer to an ‘Ideal Inhaler’ with the Easyhaler®

An Innovative Dry Powder Inhaler
  • Henry Chrystyn
Review Article

Abstract

The characteristics of an ideal inhaler are based around the design and formulation of the device, patient use and the clinical effect, together with concordance and patient preference. To ensure consistent drug delivery to the lungs, with regular adherence to the prescribed dosage regimen, it is essential that all these characteristics simultaneously interact to provide smooth and sustained therapeutic control affected only by the clinical status of the patient. The literature highlights that dose emission from an Easyhaler® is fairly consistent irrespective of the inhalation technique used by patients of all age groups. Clinical studies have shown equivalence of this device to those frequently prescribed and that it is preferred by many patients. Although further research is required into the development of inhalation devices, the literature describing the Easyhaler® dry powder inhaler indicates how an inhaler can closely meet the criteria for an ideal inhaler.

Keywords

Salbutamol Budesonide Terbutaline Formoterol Lung Deposition 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgements

Prof. Chrystyn has been a consultant to and received grants to attend conferences and educational meetings from numerous companies in the Pharmaceutical Industry that market inhaled products including Ranbaxy (UK) Ltd. Prof. Chrystyn’s research group has also received funds from many of these pharmaceutical companies to carry out research. Prof. Chrystyn has no personal shares with any pharmaceutical company. He was assisted in writing this paper by Joseph Delahunty of Sante Communications [on behalf of Ranbaxy (UK) Ltd].

References

  1. 1.
    Paterson IC, Crompton GK. Use of pressurised aerosols by asthmatic patients. BMJ 1976; 1: 76–7PubMedCrossRefGoogle Scholar
  2. 2.
    Crompton GK. Problems patients have using pressurised aerosol inhalers. Eur J Respir Dis Suppl 1982; 119: 101–4PubMedGoogle Scholar
  3. 3.
    Lenney J, Innes JA, Crompton GK. Inappropriate inhaler use: assessment of use and patient preference of seven inhalation devices. Respir Med 2000; 94: 496–500PubMedCrossRefGoogle Scholar
  4. 4.
    Nimmo GJ, Chen DN, Martinusen SM, et al. Assessment of patient acceptance and inhalation technique of pressurized aerosol inhaler and two breath actuated devices. Ann Pharmacother 1993; 27: 922–7PubMedGoogle Scholar
  5. 5.
    Molina MJ, Rowland FS. Stratospheric sink for chlorofluromethanes: chlorine atom-catalysed destruction of ozone. Nature 1974; 249: 810–2CrossRefGoogle Scholar
  6. 6.
    Noakes TJ. CFCs, their replacement and the ozone layer. J Aerosol Med 1995; 8Suppl. 1: S3–7PubMedGoogle Scholar
  7. 7.
    United Nations Environmental Program (UNEP). Montreal Protocol on substances that deplete the Ozone Layer. Technology and Assessment Panel, Volumes I and II. Report Volumes I and II. The Netherlands: UNEP, 1997Google Scholar
  8. 8.
    Laursen LC. Clinical efficacy and safety of Turbuhaler as compared to pressurized MDIs-beta 2-agonists. J Aerosol Med 1994; 7Suppl. 1: S59–62PubMedGoogle Scholar
  9. 9.
    Engel T, Heinig JH, Maling HJ, et al. Clinical comparison of inhaled budesonide delivered via pressurized metered dose inhaler or Turbuhaler. Allergy 1989; 44: 220–5PubMedCrossRefGoogle Scholar
  10. 10.
    Thorsson L, Edsbacker S, Conradson TB. Lung deposition of budesonide is twice that from a pressurized metered-dose inhaler pMDI. Eur Respir J 1994; 7: 1839–44PubMedCrossRefGoogle Scholar
  11. 11.
    Vidgren P, Silvasti M, Poukkula A, et al. Easyhaler powder inhaler: a new alternative in the anti-inflammatory treatment of asthma. Acta Ther 1994; 20: 117–31Google Scholar
  12. 12.
    Chrystyn H. Methods to identify drug deposition in the lungs following inhalation. Br J Clin Pharmacol 2001; 51: 289–99PubMedCrossRefGoogle Scholar
  13. 13.
    Chrystyn H. Anatomy and physiology in delivery: can we define our targets? Allergy 1999; 54: 82–7PubMedCrossRefGoogle Scholar
  14. 14.
    Cripps A, Riebe M, Schulze M, et al. Pharmaceutical transition to non-CFC pressurized metered dose inhalers. Respir Med 2000; 94Suppl. B: S3–9PubMedGoogle Scholar
  15. 15.
    Chrystyn H. Is inhalation rate important for a dry powder inhaler? Using the in-check dial to identify these rates. Respir Med 2003; 97: 181–7PubMedCrossRefGoogle Scholar
  16. 16.
    Cyr TD, Graham SJ, Li KY, et al. Low first-spray drug content in albuterol metered-dose inhalers. Pharm Res 1991; 8(5): 658–60PubMedCrossRefGoogle Scholar
  17. 17.
    Graham SJ, Lawrence RC, Ormsby ED, et al. Particle size distribution of single and multiple sprays of salbutamol metered-dose inhalers (MDIs). Pharm Res 1995; 12(9): 1380–4PubMedCrossRefGoogle Scholar
  18. 18.
    LeBelle M, Pike RK, Graham SJ, et al. Metered-dose inhalers. I: drug content and particle size distribution of beclomethasone dipropionate. J Pharm Biomed Anal 1996; 14: 793–800PubMedCrossRefGoogle Scholar
  19. 19.
    Cyr TD, Duhaime RM, Graham SJ, et al. Metered dose inhalers. III: metaproterenol sulphate; particle size distribution and dose uniformity. J Pharm Biomed Anal 1997; 15: 1709–18PubMedCrossRefGoogle Scholar
  20. 20.
    Tarsin W, Assi KH, Chrystyn H. In-vitro intra- and inter-inhaler flow rate-dependent dosage emission from a combination of budesonide and eformoterol in a dry powder inhaler. J Aerosol Med 2004; 17: 25–32PubMedCrossRefGoogle Scholar
  21. 21.
    Palander A, Mattila T, Karka M, et al. In vitro comparison of three salbutamol-containing multidose dry powder inhalers. Clin Drug Invest 2000; 20: 25–33CrossRefGoogle Scholar
  22. 22.
    Chrystyn H, Corrado OJ, Brownlee K, et al. Inhalation rates of asthmatic children (CHILD) and adults and of chronic obstructive pulmonary disease (COPD) patients through inhalers. Am J Respir Crit Care Med 2002; 165: A190Google Scholar
  23. 23.
    Tarsin W, Hawksworth GM, Haslam GM, et al. Inter- and intravariability of inhalation rates when patients use their dry powder inhalers (DPI) [Abstract]. Thorax 2001; 56Suppl. 3: 60Google Scholar
  24. 24.
    Tarsin WY, Assi KA, Pearson SB, et al. Ex-vivo emitted dose characterisation for combination formulations in dry powder inhalers (DPI) [Abstract]. Eur Respir J 2003; 22Suppl. 45: 472sGoogle Scholar
  25. 25.
    Pedersen S, Hansen OR, Fuglsang G. Influence of inspiratory flow rate upon the effect of a Turbuhaler. Arch Dis Child 1990; 65: 308–10PubMedCrossRefGoogle Scholar
  26. 26.
    Nsour WM, Alldred A, Corrado OJ, et al. Measurement of peak inhalation rates with an In-Check Meter® to identify an elderly patient’s ability to use a Turbuhaler®. Respir Med 2001; 95: 965–8PubMedCrossRefGoogle Scholar
  27. 27.
    Malmstrom K, Sorva R, Silvasti M. Application and efficacy of the multi-dose dry powder inhaler, Easyhaler®, in children with asthma. Pediatr Allergy Immunol 1999; 10: 66–70PubMedCrossRefGoogle Scholar
  28. 28.
    Hirst PH, Bacon RE, Pitcairn GR, et al. A comparison of the lung deposition of budesonide from Easyhaler®, Turbuhaler® and pMDI plus spacer in asthmatic patients. Respir Med 2001; 95: 720–7PubMedCrossRefGoogle Scholar
  29. 29.
    Koskela T, Malmstrom K, Sairanen U, et al. Efficacy of salbutamol via Easyhaler® unaffected by low inspiratory flow. Respir Med 2000; 94: 1229–33PubMedCrossRefGoogle Scholar
  30. 30.
    Koskela T, Hedman J, Ekroos H, et al. Equivalence of two steroid-containing inhalers: Easyhaler multidose powder inhaler compared with conventional aerosol with large-volume spacer. Respiration 2000; 67: 194–202PubMedCrossRefGoogle Scholar
  31. 31.
    Vidgren M, Silvasti M, Korhonen P, et al. Clinical equivalence of a novel multiple dose powder inhaler versus a conventional metered dose inhaler on bronchodilating effects of salbutamol. Drug Res 1995; 45: 44–7Google Scholar
  32. 32.
    Malinen A, Hedman J, Koskela T, et al. Salbutamol via Easyhaler® produces equivalent bronchodilation to terbutaline via Turbuhaler® following inhalation of a single dose of equipotent β2-sympathomimetic. Clin Drug Invest 2000; 20: 165–71CrossRefGoogle Scholar
  33. 33.
    Vanto T, Hamalainen KM, Vahteristo M, et al. Comparison of two budesonide dry powder inhalers in the treatment of asthma in children. J Aerosol Med 2004; 17: 15–24PubMedCrossRefGoogle Scholar
  34. 34.
    Schweisfurth H, Malinen A, Koskela T, et al. Comparison of two budesonide powder inhalers, Easyhaler® and Turbuhaler®, in steroid naive asthmatic patients. Respir Med 2002; 96: 599–606PubMedCrossRefGoogle Scholar
  35. 35.
    Lahelma A, Kirjavainen M, Kela M, et al. Equivalent lung depostion of budesonide in vivo: a comparison of dry powder inhalers using a pharmacokinetic method. Br J Clin Pharmacol 2005 Feb; 59(2): 167–73PubMedCrossRefGoogle Scholar
  36. 36.
    Hamalainen KM, Granander M, Toivanen P, et al. Assessment of the systemic effects of budesonide inhaled from Easyhaler® and from Turbuhaler® in healthy male volunteers. Respir Med 2001; 95: 863–9PubMedCrossRefGoogle Scholar
  37. 37.
    Tukiainen H, Rytila P, Hamalainen KM, et al. Safety, tolerability and acceptance of two dry powder inhalers in the administration of budesonide in steroid-treated asthmatic patients. Respir Med 2002; 96: 221–9PubMedCrossRefGoogle Scholar
  38. 38.
    Rand CS, Wise RA. Measuring adherence to asthma medication regimens. Am J Respir Crit Care Med 1994; 149: 69–76Google Scholar
  39. 39.
    Child F, Davies S, Clayton S, et al. Inhaler devices for asthma: do we follow the guidelines? Arch Dis Child 2002; 86: 176–9PubMedCrossRefGoogle Scholar
  40. 40.
    Ahonen A, Leinonen M, Ranki-Pesonen M. Patient satisfaction with Easyhaler® compared with other inhalation systems in the treatment of asthma: a meta-analysis. Curr Ther Res Clin Exp 2000; 61: 61–73Google Scholar

Copyright information

© Adis Data Information BV 2006

Authors and Affiliations

  1. 1.School of Pharmacy and Institute of Pharmaceutical InnovationUniversity of BradfordWest Yorkshire, BradfordUK

Personalised recommendations